

**IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**

In re: OXYCONTIN ANTITRUST LITIGATION	04-md-1603 (SHS) This document relates to the following cases:
PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES, and GRÜNENTHAL GMBH, Plaintiffs/Counterclaim Defendants, v. TEVA PHARMACEUTICALS USA, INC., Defendant/Counterclaim Plaintiff.	Case No. 11-cv-02037 (SHS) ECF Case
PURDUE PHARMA L.P. and GRÜNENTHAL GMBH, Plaintiffs/Counterclaim Defendants, v. TEVA PHARMACEUTICALS USA, INC., Defendant/Counterclaim Plaintiff.	Case No. 12-cv-05083 (SHS) ECF Case

**PLAINTIFF AND COUNTERCLAIM DEFENDANT GRÜNENTHAL'S
NOTICE OF APPEAL TO THE UNITED STATES
COURT OF APPEALS FOR THE FEDERAL CIRCUIT**

Notice is hereby given that Plaintiff and Counterclaim Defendant Grünenthal GmbH (“Grünenthal”) appeals in each of the above-named actions to the United States Court of Appeals for the Federal Circuit from the judgments and orders listed below:

- (1) the Judgment entered on January 22, 2014, in *Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes Technologies, & Grünenthal GmbH v. Teva Pharmaceuticals USA, Inc.*, Case No. 11-cv-02037 (SHS) (“the 02037 Action”), (D.I. 150), *Purdue Pharma L.P. & Grünenthal GmbH v. Teva Pharmaceuticals USA, Inc.*, Case No. 12-cv-

05083 (SHS) (“the 05083 Action”), (D.I. 46), and *In re Oxycontin Antitrust Litigation*, Case No. 04-md-1603 (SHS) (“the Oxycontin Litigation”), (D.I. 637), and the Findings of Facts and Conclusions of Law dated January 14, 2014, in the 02037 Action, (D.I. 149), the 05083 Action, (D.I. 45), and the Oxycontin Litigation, (D.I. 634), each denying Grünenthal’s requests for relief;

(2) the Claim Construction Opinion & Order dated August 23, 2013, in the 02037 Action, (D.I. 102), the 05083 Action, (D.I. 27), and the Oxycontin Litigation, (D.I. 568); and

(3) all opinions, orders, and rulings subsumed therein and made prior and after thereto resulting in final judgment adverse to Grünenthal’s requests for relief.

Included herewith is payment of the Notice of Appeal fee (\$505.00) as required by 28 U.S.C. § 1917 and Federal Circuit Rule 52(a)(3)(A), and Federal Rules of Appellate Procedure Rule 3(e).

Respectfully submitted,

**FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER LLP**

Dated: February 12, 2014

By: /s/ Basil J. Lewris
Basil J. Lewris
Joann M. Neth
Jennifer H. Roscetti
Erin M. Sommers
901 New York Avenue, N.W.
Washington, DC 20001
(202) 408-4000
bill.lewris@finnegan.com
joann.neth@finnegan.com
jennifer.roscetti@finnegan.com
erin.sommers@finnegan.com

Anthony C. Tridico
Finnegan Europe LLP
16 Old Bailey, London EC4M 7EG,
United Kingdom
anthony.tridico@finnegan.com

Of Counsel for Grünenthal GmbH

WILK AUSLANDER LLP
Stephen B. Hoffman
1515 Broadway, 43rd Floor
New York, NY 10036
(212) 981-2300
shoffman@wilkauslander.com

*Attorney for Plaintiff/Counterclaim Defendant
Grünenthal GmbH*